Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
1,251
archived clinical trials in
Pneumonia

Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Pittsburgh Medical Center
974
mi
from
Pittsburgh, PA
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Pittsburgh Medical Center
974
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
University of Texas Southwestern Medical Center
349
mi
from
Dallas, TX
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
University of Texas Southwestern Medical Center
349
mi
from
Dallas, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Houston Methodist Research Institute
572
mi
from
Houston, TX
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Houston Methodist Research Institute
572
mi
from
Houston, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
The University of Texas - Health Science Center & Medical School at Houston
573
mi
from
Houston, TX
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
The University of Texas - Health Science Center & Medical School at Houston
573
mi
from
Houston, TX
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
University Clinic Carl Gustav Carus
5040
mi
from
Dresden,
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
University Clinic Carl Gustav Carus
5040
mi
from
Dresden,
Click here to add this to my saved trials
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Status: Enrolling
Updated:  12/31/1969
Georgetown University Medical Center - Department of Rheumatology
1124
mi
from
Washington,
Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT
A Dose-Ranging Study of the Efficacy and Safety of Bardoxolone Methyl in Patients With Pulmonary Hypertension
Status: Enrolling
Updated: 12/31/1969
Georgetown University Medical Center - Department of Rheumatology
1124
mi
from
Washington,
Click here to add this to my saved trials
Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions
Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions
Status: Enrolling
Updated:  12/31/1969
Temple University Hospital
1225
mi
from
Philadelphia, PA
Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions
Specialized Community Disease Management to Reduce Substance Use and Hospital Readmissions
Status: Enrolling
Updated: 12/31/1969
Temple University Hospital
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery
Status: Enrolling
Updated:  12/31/1969
Mstcvs-Qc
806
mi
from
Ann Arbor, MI
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery
Status: Enrolling
Updated: 12/31/1969
Mstcvs-Qc
806
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2
Status: Enrolling
Updated:  12/31/1969
Mstcvs-Qc
806
mi
from
Ann Arbor, MI
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2
Optimizing Prevention of Healthcare-Acquired Infections After Cardiac Surgery (HAI)_2
Status: Enrolling
Updated: 12/31/1969
Mstcvs-Qc
806
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
PATient Navigator to rEduce Readmissions
PATient Navigator to rEduce Readmissions
Status: Enrolling
Updated:  12/31/1969
University of Illinois Hospital
608
mi
from
Chicago, IL
PATient Navigator to rEduce Readmissions
PATient Navigator to rEduce Readmissions
Status: Enrolling
Updated: 12/31/1969
University of Illinois Hospital
608
mi
from
Chicago, IL
Click here to add this to my saved trials
Assessing NOS Uptake With PET Imaging in Lung Inflammation
Assessing [18F](+/-)NOS Uptake With PET Imaging in Endotoxin-induced Lung Inflammation
Status: Enrolling
Updated:  12/31/1969
Washington University School of Medicine @ Barnes-Jewish Hospital
415
mi
from
Saint Louis, MO
Assessing NOS Uptake With PET Imaging in Lung Inflammation
Assessing [18F](+/-)NOS Uptake With PET Imaging in Endotoxin-induced Lung Inflammation
Status: Enrolling
Updated: 12/31/1969
Washington University School of Medicine @ Barnes-Jewish Hospital
415
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1358
mi
from
Hartford, CT
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1358
mi
from
Hartford, CT
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
932
mi
from
Augusta, GA
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
932
mi
from
Augusta, GA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
610
mi
from
Chicago, IL
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
610
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
610
mi
from
Chicago, IL
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
610
mi
from
Chicago, IL
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
613
mi
from
Evanston, IL
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
613
mi
from
Evanston, IL
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
643
mi
from
Indianapolis, IN
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
643
mi
from
Indianapolis, IN
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
841
mi
from
Detroit, MI
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
841
mi
from
Detroit, MI
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
839
mi
from
Royal Oak, MI
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
839
mi
from
Royal Oak, MI
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1263
mi
from
New Brunswick, NJ
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1263
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1056
mi
from
Buffalo, NY
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1056
mi
from
Buffalo, NY
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1296
mi
from
Flushing, NY
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1296
mi
from
Flushing, NY
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1290
mi
from
New York, NY
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1051
mi
from
Durham, NC
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1051
mi
from
Durham, NC
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
895
mi
from
Cleveland, OH
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
895
mi
from
Cleveland, OH
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1053
mi
from
Charlottesville, VA
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1053
mi
from
Charlottesville, VA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1117
mi
from
Tampa, FL
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1117
mi
from
Tampa, FL
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
959
mi
from
Charlotte, NC
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
959
mi
from
Charlotte, NC
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1225
mi
from
Philadelphia, PA
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1225
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
971
mi
from
Pittsburgh, PA
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
971
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
5602
mi
from
Ciudad Autonoma de Buenos Aires,
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
5602
mi
from
Ciudad Autonoma de Buenos Aires,
Click here to add this to my saved trials
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1291
mi
from
Bronx, NY
Efficacy, Safety, Tolerability of Vabomere Compared to Best Available Therapy in Treating Serious Infections in Adults
A Phase 3, Multi-Center, Randomized, Open-Label Study of Vabomere(Meropenem-vaborbactam) Versus Best Available Therapy in Subjects With Selected Serious Infections Due to Carbapenem-Resistant Enterobacteriaceae (CRE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1291
mi
from
Bronx, NY
Click here to add this to my saved trials
Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults
A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of MEDI3902 in Healthy Adults
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1320
mi
from
South Miami, FL
Phase 1 Randomized Double-blind Placebo Controlled Study to Evaluate Safety and PK of MEDI3902 in Healthy Adults
A Phase 1 Randomized, Double-blind, Placebo-controlled Study to Evaluate the Safety and Pharmacokinetics of MEDI3902 in Healthy Adults
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1320
mi
from
South Miami, FL
Click here to add this to my saved trials
Telavancin Observational Use Registry (TOUR)
Telavancin Observational Use Registry (TOUR)
Status: Enrolling
Updated:  12/31/1969
Newland Medical Associates
835
mi
from
Southfield, MI
Telavancin Observational Use Registry (TOUR)
Telavancin Observational Use Registry (TOUR)
Status: Enrolling
Updated: 12/31/1969
Newland Medical Associates
835
mi
from
Southfield, MI
Click here to add this to my saved trials
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
740
mi
from
Mobile, AL
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
740
mi
from
Mobile, AL
Click here to add this to my saved trials
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
841
mi
from
Detroit, MI
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
841
mi
from
Detroit, MI
Click here to add this to my saved trials
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated:  12/31/1969
4772
mi
from
Liege,
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated: 12/31/1969
4772
mi
from
Liege,
Click here to add this to my saved trials
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1056
mi
from
Buffalo, NY
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1056
mi
from
Buffalo, NY
Click here to add this to my saved trials
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1217
mi
from
Ventura, CA
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1217
mi
from
Ventura, CA
Click here to add this to my saved trials
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
620
mi
from
Zachary, LA
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
620
mi
from
Zachary, LA
Click here to add this to my saved trials
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
746
mi
from
Dayton, OH
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
746
mi
from
Dayton, OH
Click here to add this to my saved trials
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
683
mi
from
Birmingham, AL
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
683
mi
from
Birmingham, AL
Click here to add this to my saved trials
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1311
mi
from
Stamford, CT
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1311
mi
from
Stamford, CT
Click here to add this to my saved trials
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
1150
mi
from
Laguna Hills, CA
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
1150
mi
from
Laguna Hills, CA
Click here to add this to my saved trials
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
553
mi
from
Saint Paul, MN
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
553
mi
from
Saint Paul, MN
Click here to add this to my saved trials
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
836
mi
from
Huntington, WV
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
836
mi
from
Huntington, WV
Click here to add this to my saved trials
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
418
mi
from
Saint Louis, MO
Omadacycline vs Moxifloxacin for the Treatment of CABP (EudraCT #2013-004071-13)
A Phase 3 Randomized, Double-Blind, Multi-Center Study to Compare the Safety and Efficacy of Omadacycline Intravenous (IV)/Oral (PO) to Moxifloxacin IV/PO for Treating Adults Subjects With Community-Acquired Bacterial Pneumonia
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
418
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated:  12/31/1969
Banner - University Medical Center Advanced Lung Disease Clinic - Phoenix
852
mi
from
Phoenix, AZ
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated: 12/31/1969
Banner - University Medical Center Advanced Lung Disease Clinic - Phoenix
852
mi
from
Phoenix, AZ
Click here to add this to my saved trials
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated:  12/31/1969
Mayo Clinic, Scottsdale - Infectious Diseases
842
mi
from
Scottsdale, AZ
Efficacy Study of Fluconazole to Treat Coccidioidomycosis Pneumonia (Valley Fever)
A Randomized, Double-blind, Placebo-controlled Clinical Trial of Fluconazole as Early Empiric Treatment of Coccidioidomycosis Pneumonia (Valley Fever) in Adults Presenting With Community Acquired Pneumonia (CAP) in Endemic Areas (FLEET-Valley Fever)
Status: Enrolling
Updated: 12/31/1969
Mayo Clinic, Scottsdale - Infectious Diseases
842
mi
from
Scottsdale, AZ
Click here to add this to my saved trials